METTL3 and neoplasm: Importantly, we found that the combination of high tumour METTL3 levels and intratumoural CD33+ MDSCs was significantly correlated with poor DFS [HR (95% CI): 7.673 (2.420–24.324), P = 0.001] and OS [HR (95% CI): 7.286 (2.667–19.902), P < 0.001] in patients with advanced disease stages (Table 3), suggesting that the combination of high METTL3 levels and CD33+ MDSCs improved patient prognostic stratification in those with advanced disease.